Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.56 |
| ▸ | TUBB | P07437 | 2/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23657593 | 0.83 | LMNA (0.72) | DNMT3ALMNAHPGDNLRP3 | |
| SCHEMBL23675446 | 0.82 | TUBB (0.72) | LMNAP2RX1TMPRSS4TUBBKCNMA1 | |
| SCHEMBL13812914 | 0.82 | P2RX1 (0.66) | LMNAP2RX1TMPRSS4TUBB | |
| SCHEMBL13753989 | 0.82 | LMNA (0.62) | DNMT3ALMNATRPV1KCNMA1HPGD | |
| SCHEMBL28871890 | 0.81 | HDAC3 (0.67) | DNMT3ALMNATUBBHPGD | |
| SCHEMBL30080912 | 0.81 | HDAC3 (0.67) | DNMT3ALMNATUBBHPGD | |
| SCHEMBL11516368 | 0.81 | LMNA (0.68) | DNMT3ALMNAKCNMA1HPGDNLRP3 | |
| SCHEMBL26097052 | 0.80 | HPGD (0.63) | LMNAP2RX1TMPRSS4TUBBHPGD | |
| SCHEMBL5065588 | 0.80 | TRPV1 (0.59) | LMNATRPV1HPGD | |
| SCHEMBL26098397 | 0.79 | P2RX1 (0.64) | LMNAP2RX1TMPRSS4TUBBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BIOPHAGY INC (US) | 2021-12-28 | — | — | US | disclosed |
| WO-2020131924-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | Biophagy, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BIOPHAGY INC (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190007-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USE IN TREATING AUTOPHAGY-ASSOCIATED DISORDERS | BECN1, ATG7, SQSTM1 | DNMT3A 3973/4885LMNA 372/4885TRPV1 1863/4885 |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BECN1, ATG7, SQSTM1 | DNMT3A 3973/4885LMNA 372/4885TRPV1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.